Approval · Notice of Compliance 31429 · 2023
MS CONTIN: Notice of Compliance 31429
Issued August 15, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31429
- Date
- August 15, 2023
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Updates to the Product Monograph (PM)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MS CONTIN | Not yet assigned | — |
Medicinal ingredients
- MORPHINE SULFATE 15 MG per TAB
- MORPHINE SULFATE 30 MG per TAB
- MORPHINE SULFATE 60 MG per TAB
- MORPHINE SULFATE 100 MG per TAB
- MORPHINE SULFATE 200 MG per TAB